Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00719173 · ClinicalTrials.gov registry record · Phase 1

Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer

A Phase 1 study of Breast Cancer and Nausea and Vomiting, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
Phase 1
Development phase
19
Enrollment target
1
Study location

NCT00719173 is a Phase 1 study of Breast Cancer and Nausea and Vomiting that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 19 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00719173, a Phase 1 study of Breast Cancer and Nausea and Vomiting, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Antiemetic drugs, such as aprepitant, may help lessen or prevent nausea and vomiting in patients undergoing chemotherapy. PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to placebo in preventing nausea and vomiting in patients undergoing chemotherapy for breast cancer.

Conditions Studied

Breast Cancer Nausea and Vomiting

Interventions

  • OTHER placebo
  • DRUG cyclophosphamide
  • DRUG aprepitant

Study Locations (1)

North Carolina

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2005-08
Est. Completion 2010-10
Phase Phase 1

Sponsor

UNC Lineberger Comprehensive Cancer Center

366 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00719173

The ClinicalTrials.gov registry entry for NCT00719173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT00719173 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00719173 about?

NCT00719173 is a clinical study titled "Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer". RATIONALE: Antiemetic drugs, such as aprepitant, may help lessen or prevent nausea and vomiting in patients undergoing chemotherapy. PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to placebo in preventing nausea and vomiting in patients undergoing c...

What is the current status of trial NCT00719173?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2005-08. Estimated completion is 2010-10.

What conditions does trial NCT00719173 study?

This clinical trial studies the following conditions: Breast Cancer, Nausea and Vomiting.

What interventions are being tested in trial NCT00719173?

The interventions under investigation include: placebo (OTHER), cyclophosphamide (DRUG), aprepitant (DRUG).

Who is sponsoring clinical trial NCT00719173?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00719173 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Nausea and Vomiting

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.